Lexaria Bioscience Corp LEXX

Facebook update

[shawk]

https://www.facebook.com/groups/1664919466872085/permalink/1668702153160483/
Quote:

---

Dear Lexaria Subscribers, 


Lexaria Updates 
Lexaria is in the midst of its busiest period ever: we’ve never had as many initiatives to manage at once as we do today. Perversely it is because of our hectic pace that we’ve not communicated to our growing audience of stakeholders as well as we should. 

So… an update and peak behind the scenes of Lexaria Bioscience. 

Save the Date: Lexaria Web-Meeting 

November 1, 2017 at 1:15PM Pacific, Lexaria will hold its first ever Web-Meeting. We will deliver all our latest news and a short corporate presentation. We’re expecting to have a LOT to talk about – don’t miss this! This meeting is open to everyone but you must register first. 

REGISTER NOW for this important event: 

https://events.genndi.com/register/169105139238467429/ce8311a9b6 


Intellectual Property 
As you all know, we received our first US-granted patent in October 2016 which was followed up by the award of the same patent in Australia in June 2017. That patent, for the delivery of all non-psychoactive cannabinoids, was a watershed event in the history of Lexaria that added value and credibility. 

We’ve said repeatedly that we hope for further patent granted status prior to the end of 2017 – this would be in accordance with expected normal processing and examination timelines from the United States Patent and Trademark Office (USPTO). We’re hopeful that the patent award utilizing our delivery platform for psychoactive cannabinoids will be next. 

As important as each individual patent is and will be, Lexaria is also eager to underline the fact that our technology is a delivery platform believed to be applicable to many different types of drugs, vitamins and other substances. It is the applicability of our tech in delivering a substance more efficiently that provides its most substantive value: for example we may be able to deliver existing and new drugs better than the owner of that drug can do so! This does not invalidate either the patents and IP of the drug owner nor does it invalidate the patents and IP of Lexaria: instead, our technology has the ability to become a value-added “layer” for improved delivery of the other drug. 

We’ve recently instructed our patent attorneys to take the necessary steps to accelerate examinations of many of our patent applications wherever possible. We expect national patent examinations, and hopefully awards, in many countries in the months and years to come. 

Research & Development 
We’re working on several parallel paths towards development of new products and new applications for our technology; and to discover new technologies that complement our own. Our jointly funded, collaborative work with Canada’s National Research Council (NRC) began in June and is progressing methodically as we investigate molecular associations that may lie at the heart of our technology. This 18-month program is expected to wrap up in the 2nd half of 2018 with interim results possible before then. 

More recently we announced a clinical study to be conducted at the University of British Columbia to investigate cardiovascular response and cognitive performance associated with our originally-formulated TurboCBDTM product that utilizes our DehydraTECHTM technology. All ethical board and independent review board examinations are complete and passed and the study design is virtually complete with a view to commencing subject enrollment and testing soon. 

In addition, the UBC/Lexaria study was recently registered with the National Institute of Health (NIH) and can be found at https://clinicaltrials.gov/ct2/show/NCT03295903. This clinical study includes a rigorous set of data collection that will include blood pressure and blood flow testing, oxygen levels, pharmacokinetic (PK) data on cannabidiol absorption and levels over time through blood testing, and even metabolites of cannabidiol within the blood as we try to better understand what proportion of the base ingredient might be metabolized by the liver versus that portion that might be absorbed through the lymphatic circulatory system per our theories of the mode of action of the DehydraTECH™ technology. Answers to these questions could have profound impact on future applicability of our technology with other payload molecules. 

The UBC/Lexaria study should be underway with data collection from the first of the expected 24 volunteers within the next 30-60 days. 

Separate from both of these studies, we are also nearing the end of our internal design phase of a nicotine absorption study expected to begin soon. This in vivo study will provide PK data and more, in animals, of the delivery of nicotine in edible format for the first time in the world utilizing the Lexaria DehydraTECH™ technology to make the delivery more palatable and effective. This study will be conducted at a respected third-party laboratory facility in Philadelphia. It will provide our first hard data related to the use of Lexaria’s technology outside of the cannabinoid sector and thus could help to open the door to eventual new business opportunities. 

A note of caution to our followers: science is unpredictable and results from any new tests can vary widely. More often than not, follow-up studies are required in order to understand new processes more fully, and to optimize technologies. In other words: we might be so lucky as to score a home-run in any initial study – but more likely we’ll need a number of R&D projects focused on a single theme to develop a thorough understanding. 

Regulatory 
In Canada, the Toronto Stock Exchange issued staff guidance related to TSX-listed cannabis-related companies doing business in the USA and listed on the TSX. This guidance seems to be establishing TSX policy that US federal law trumps US state law, and therefore casts some uncertainty onto the continued trading of companies with US cannabis business exposure on the TSX. Lexaria Bioscience does NOT trade on the TSX, instead we trade on the Canadian Securities Exchange (CSE) which has been very clear that so long as full disclosure is made to shareholders about US-based activities, compliance with State Laws is sufficient. 

In addition, the Canadian Securities Administrators (CSA) issued staff notice 51-352 reiterating that it requires a disclosure based approach related to all marijuana related business activities in order to comply with its expectations. 

Lexaria does not grow, work with or sell any marijuana or marijuana related product. Lexaria works with hemp-related products only. Lexaria also licenses its technology to state-registered cannabis companies and in that way provides a service just as ATT might provide a phone service, or PG&E might provide electricity to a cannabis company; neither of which could be construed to then be itself a cannabis company. 

Lexaria is in compliance with all published requirements of its regulators in Canada and does not believe the recent TSX staff guidance affects CSE-listed securities. Shareholders should rest assured that Lexaria will always work hard to adapt to changing regulatory landscapes and remain in compliance. 

Commercial Application 
Every company needs to commercialize its technology and demonstrate that the market is willing to adopt and pay for new ideas. Lexaria has already done so with our first Licensee in Colorado, a start-up brand that is gaining considerable market traction utilizing and paying for our technology since late 2016. More established brands require much more work: existing large brands need to ensure new formulations are compatible with the needs of their existing customers. That’s why Lexaria works hard behind the scenes with its potential Licensees, to ensure the consumer products are “just right”. The improvements we offer to the end customer – typically some combination of improved taste, faster onset, and/or increased bioavailability and therefore potency – can require new product packaging, legal review for product claims, and even slightly altered manufacturing processes. Those needs, along with extensive and repeated rounds of testing to make the perfect recipe, take time. 

Nonetheless we are currently collaborating with leading cannabinoid firms in Colorado, California, Nevada, Canada and elsewhere to utilize the Lexaria DehydraTECH™ technology within their existing cannabinoid edible products. We expect to have positive developments to announce in Q1 or Q2, 2018, or even earlier. We also recently revamped our corporate website at www.lexariabioscience.com with a view to continually attracting new prospective licensees and partnering interest as we continue to grow the business. 

Corporate 
Lexaria raised roughly US$4 million (CDN$5 million) from November 2016 through May 2017. We have no debt and have a healthy cash balance in our bank accounts. We believe we have sufficient cash to follow through with all the R&D noted above; all the product development we are working on; and fund our general corporate needs through to the end of 2018. We had communicated to our stakeholders in mid-and-late 2016 that we recognized the necessity of fixing our balance sheet, and we did it. 

We have no current plans to raise additional equity capital to fund the company under the present circumstances. We can foresee positive potential circumstances with increased valuations, or important strategic corporate opportunities, whereby we might take advantage of the opportunity to strengthen our balance sheet even more. We are also aware that we might experience significantly improved cash flows in 2018 compared to 2016 and 2017, and that revenue growth could be strong enough to offset any need for new capital. We are strong and healthy. 


For all the latest news and updates while on the go just text


"lexaria" to 76000. 

Are you on Twitter, Facebook or Google+? Do not forget to look us up or just click on the buttons below. Give us a follow and a like. Also do not forget to check out our website for all the latest news and updates on Lexaria Bioscience Corp. 

This email is sent by Lexaria Bioscience Corp., 156 Valleyview Rd, Kelowna, BC V1X 3M4 Canada. See www.lexariabioscience.com for more information.

---